Enfortumab vedotin (EV) is the first drug in this new ... Given the extremely promising results of the EV-302 trial, which showed a near doubling of survival with the combination therapy of ...

The indication is based on results of the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39). The Phase 3 clinical ...

This would involve the FDA granting a conditional licence that would be confirmed by a larger phase 3 study, EV-301, which is ongoing. Concluding, Petrylak said enfortumab vedotin “has the ...